Table 1.
Demographic and clinical variables of the study patients upon entry
| Pantoprazole 192 mg day−1 | Pantoprazole 160 mg day−1 | |
|---|---|---|
| (n= 60) | (n= 60) | |
| Age, mean (years) | 65.5 (20.4–82.7) | 64.5 (20.2–80.7) |
| Male gender (%) | 40 (66.7%) | 42 (70%) |
| Location of ulcer (%) | ||
| Stomach | 43 (71.7%) | 38 (63.3%) |
| Duodenum | 17 (28.3%) | 22 (36.7%) |
| Endoscopic findings (%) | ||
| Spurting | 5 (8.3%) | 7 (11.7%) |
| Oozing | 22 (36.7%) | 18 (30%) |
| NBVV | 25 (41.7%) | 27 (45%) |
| Clot | 8 (13.3%) | 8 (13.3%) |
| Gastric contents (%) | ||
| Blood | 20 (33.3%) | 22 (36.7%) |
| Coffee grounds | 25 (41.7%) | 24 (40%) |
| Clear | 15 (25%) | 14 (23.3%) |
| Shock (%) | 12 (20%) | 10 (16.7%) |
| Ulcer size (cm) | 1.05 (0.4–2.0) | 1.10 (0.5–2.1) |
| Helicoibacter pylori infection (%) | 38 (63.3%) | 40 (66.7%) |
| Rockall score | 5.05 (3.8–7.0) | 4.98 (3.5–6.9) |
Numerical variables expressed as mean with 95% confidence interval of distribution. There was no statistically significant difference between the two groups. NBVV, nonbleeding visible vessel.